Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (196 reviews)

For research use only.

Catalog No.S2807 Synonyms: GSK2118436A

196 publications

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436, GSK2118436A) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 196 publications

Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3

PubMed: 33619394 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2021, 7(24)eabg0390

PubMed: 34108213 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1747

PubMed: 33741929 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(8):4421-4440

PubMed: 33849069 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-020-01628-x

PubMed: 33500549 ( click the link to review the publication )

Sci Signal, 2021, 14(682)eabc1648

PubMed: 33975980 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2175

PubMed: 33946525 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):85

PubMed: 33446653 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):127

PubMed: 34059622 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Endocr Relat Cancer, 2021, 28(5):311-324

PubMed: 33769310 ( click the link to review the publication )

Neoplasia, 2021, 23(5):539-550

PubMed: 33971465 ( click the link to review the publication )
Biomolecules, 2021, 11(2)153

PubMed: 33503908 ( click the link to review the publication )

Front Oncol, 2021, 11:656453

PubMed: 33898322 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(4)1801

PubMed: 33670365 ( click the link to review the publication )

Mol Imaging Biol, 2021, 10.1007/s11307-021-01615-y

PubMed: 34101107 ( click the link to review the publication )

Eur J Pharmacol, 2021, 906:174214

PubMed: 34116044 ( click the link to review the publication )

Biomed Chromatogr, 2021, e5205

PubMed: 34192355 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)14

PubMed: 33649790 ( click the link to review the publication )

J Physiol Biochem, 2021, 10.1007/s13105-021-00789-x

PubMed: 33587254 ( click the link to review the publication )

Cancer Immunol Res, 2021, 10.1158/2326-6066.CIR-20-0905

PubMed: 33653716 ( click the link to review the publication )

Mol Carcinog, 2021, 60(3):201-212

PubMed: 33595872 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

EMBO Rep, 2020, e50163

PubMed: 33369872 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancer Lett, 2020, 495:135-144

PubMed: 32979462 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2981

PubMed: 33066704 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):973

PubMed: 33184267 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

ACS Infect Dis, 2020, acsinfecdis.0c00486

PubMed: 33183004 ( click the link to review the publication )
Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )

ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Vet Pathol, 2020, 300985820967449

PubMed: 33205710 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31105-31113

PubMed: 33229534 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cancer Res, 2019,

PubMed: 31362929 ( click the link to review the publication )
Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )
Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )
Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )
Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )
Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	Mm\lT4lv[XOnIFHzd4F6				M3zVVWlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDIbZMhfGGpZ3XkJGIuWmGoIG[2NFBGKG23dHHueEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KGOxLXX4dJJme3OrbnegR2REOzdiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[mmxdHnufYxifGWmLV3FT{Bxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDifUBCdHCqYWPjdoVmdiCjc4PhfUB4cXSqIFnDOVAhd2ZiMD6wNFA4KM7:TR?=	M3vTNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
SK-MEL-28	M1K5b2tqdmG\|ZTDBd5NigQ>?		M17uVFEhcA>?		Mk\sTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGVTUyCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFA1KM7:TR?=	M{XNT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
HepG2	NEjNVoJMcW6jc3WgRZN{[Xl?				NGH6SHdKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1?	NF3QO\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
COLO205	M3rGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjrWY5KdmirYnn0bY9vKG:oIHj1cYFvKEORTF:yNFUh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	NGTqVWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
HepG2	MX3GeY5kfGmxbjDBd5NigQ>?		NGXUZVg1PSCvaX6=	M2nrXWROW09?	M2LURmlvcGmkaYTpc44hd2ZiQXzrOUBqdiCWR1[tZoV1[S2\|dHnteYxifGWmIHj1cYFvKEincFeyJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFOvYXSyJJBpd3OyaH;yfYxifGmxbjD0doVifGWmIH\vdkA1PSCvaX7zJJBzcW:{IITvJHRITi2kZYThJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFYxKG2rboOgZpkhd2S7c4PlfUBjdG:2IIPjZY5v\XJiYX7hcJl{cXNid3n0bEBKSzVyIH;mJFMvPyEQvF2=	MlnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O\|MoRjJ2OUCwOlc{RC:jPh?=
HFF	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWX4d3FuOTBizszN	NH3HNoM4OiCq	M2S4RWROW09?	NXjZWo9XUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIHj1cYFvKEiIRjDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIFKtVoFnKHerdHigTWM2OCCxZjCzJO69VQ>?	NYmyUoc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzNpPkK0PVAxPjd\|PD;hQi=>
SK-MEL-28	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojJNVAh\|ryP	NFrxOlE4OiCq	NVK1UWtoTE2VTx?=	MVjJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hW0tvTVXMMVI5KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPDNizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A375P-F11	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf6NVAh\|ryP	NXzje\|RFPzJiaB?=	MVTEUXNQ	NFzmdG9KdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iQUO3OXAuTjFzIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yN{Gg{txO	Mkm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MALME-3M	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETi[oMyOCEQvF2=	MmPOO\|IhcA>?	NVywNZFbTE2VTx?=	MXjJR\|UxRTFibl2=	MmfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
UACC-62	M1jmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUWxNEDPxE1?	MUW3NkBp	M2\sfmROW09?	M3zReWlEPTB;MTDuUS=>	NX7VWZRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
C32TG	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3YZ\|hFOTBizszN	M{W0fFczKGh?	Mn\rSG1UVw>?	Mkf1TWM2OD1zIH7N	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-MEL-1	Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jGOFExKM7:TR?=	MnnXO\|IhcA>?	MmjRSG1UVw>?	Ml71TWM2OD1{IH7N	M3z6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
M14	M1nTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTkVpMyOCEQvF2=	MVu3NkBp	MnfySG1UVw>?	NE[0RY1KSzVyPUKgcm0>	NU\kUopVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-MEL-28	NEe1fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnWZ5oyOCEQvF2=	M{\NTVczKGh?	NGTySXhFVVOR	NGLJNZJKSzVyPUOgcm0>	NYniXlh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A375	NGnjV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fVNVExKM7:TR?=	NYS0RZNnPzJiaB?=	MYXEUXNQ	NWfNcGwzUUN3ME20JI5O	Mnu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
DU-4475	NV\kZWtmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnkRpo2OTBizszN	MUC3NkBp	MYnEUXNQ	MmrFTWM2OD13IH7N	M3nPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
UACC-257	NULMeItiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTLeZpYOTBizszN	M4DDbFczKGh?	NEXVcWRFVVOR	MlflTWM2OD14IH7N	NETsSWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Colo 205	NGHRdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHqzSoQyOCEQvF2=	NYTFfYxJPzJiaB?=	NF;nOG1FVVOR	MX\JR\|UxRTdibl2=	MnTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-MEL-3	NUTJUFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfwN3MzOTBizszN	NXvIRWlIPzJiaB?=	NXf2W3JWTE2VTx?=	MnH1TWM2OD15IH7N	Mn\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SH-4	NGKxc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\rNVAh\|ryP	NHvJfZg4OiCq	M4D1cWROW09?	Mli4TWM2OD16IH7N	NGPCOpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A101D	MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjxOlNYOTBizszN	MmLvO\|IhcA>?	Mn;0SG1UVw>?	MVHJR\|UxRTlibl2=	MonyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ES-2	NWPVdlhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWqxNEDPxE1?	NV22NW86PzJiaB?=	MX;EUXNQ	MkXlTWM2OD13MzDuUS=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HT-29	NVnMZYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDae2VEOTBizszN	MlXPO\|IhcA>?	M3Tq[2ROW09?	NVn2RldpUUN3ME22OkBvVQ>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW1417	M1j3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXj1c2NuOTBizszN	NYi5b3NIPzJiaB?=	MVfEUXNQ	M3\EO2lEPTB;MUW4JI5O	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW872	M{TQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnVNVAh\|ryP	M2XMflczKGh?	MoPWSG1UVw>?	NUDab2VDUUN3ME2zO\|chdk1?	M4LzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RKO	NGHuXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPZdWlkOTBizszN	MkK1O\|IhcA>?	MXjEUXNQ	NX7oOI5MUUN3ME2yMlUzOiEQvF2=	M4f0PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A673	M1nyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXmxNEDPxE1?	Mo\kO\|IhcA>?	MVXEUXNQ	M1WyU2lEPTB;MUCg{txO	MnPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
GCT	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzDNVAh\|ryP	MVm3NkBp	MnWxSG1UVw>?	NUPC[ZJ2UUN3ME2xNEDPxE1?	NHHsOWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
WM-115	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHW0NGUyOCEQvF2=	MnzjO\|IhcA>?	MnzSSG1UVw>?	MWXJR\|UxRTVibl2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
YUMAC	NIHTe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXufWEyOCEQvF2=	NETLUGc4OiCq	M{fkVGROW09?	MX3JR\|UxRTVibl2=	NYDvcVBYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OV-90	M{\CXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvKcHlLOTBizszN	M4nHPVczKGh?	Mnz6SG1UVw>?	MnvwTWM2OD1{OTDuUS=>	M122blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H508	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\R[VExKM7:TR?=	NV;1TWdRPzJiaB?=	MYXEUXNQ	M3zKR2lEPTB;MUCg{txO	NHy0[Wk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MDA-MB-231	NIXhU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmCxNVAh\|ryP	MY[3NkBp	MXLEUXNQ	MXTJR\|UxRTFyIN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW756	NFXXOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2xNEDPxE1?	MUG3NkBp	NFT2UY9FVVOR	MnrjTWM2OD1zMDFOwG0>	MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW-837	M2PqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG0c5oyOCEQvF2=	MnTiO\|IhcA>?	NHrERoFFVVOR	NH7oVZRKSzVyPUGwJO69VQ>?	NUDGUYlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UMUC-3	NIjKVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVGxNEDPxE1?	MWe3NkBp	NFnteolFVVOR	M3ewOWlEPTB;MUCg{txO	NF3vcWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
LS-174T	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6xNEDPxE1?	NX3hUGhHPzJiaB?=	NGDlNYJFVVOR	MXHJR\|UxRTFyIN88US=>	NVrYfoVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A549	NVj5eZdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSxNEDPxE1?	NX3ScmdMPzJiaB?=	MlrvSG1UVw>?	NF3IcZRKSzVyPUGwJO69VQ>?	NHvzfpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SHP-77	M3n4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfvfY05OTBizszN	NX7tO3lnPzJiaB?=	NVLDW4Q6TE2VTx?=	MkiyTWM2OD1zMDFOwG0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW480	NYGzV49rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVyxNEDPxE1?	MXq3NkBp	NVT5XoY5TE2VTx?=	MnHOTWM2OD1zMDFOwG0>	M1K0V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DLD-1	MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlG5NVAh\|ryP	Ml\rO\|IhcA>?	NI\Y[WtFVVOR	NHfhV\|JKSzVyPUGwJO69VQ>?	NIPKeZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HCT-116	NEHleodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnFNVAh\|ryP	NYTUOIlpPzJiaB?=	NX\Vc2I4TE2VTx?=	MWTJR\|UxRTFyIN88US=>	NWXEW2hrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H747	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnSNlAyOCEQvF2=	NVPBTod3PzJiaB?=	MWPEUXNQ	M130Z2lEPTB;MUCg{txO	NUnCboJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
T-84	NVnzNmhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljrNVAh\|ryP	NUPNWo15PzJiaB?=	NEnNXVRFVVOR	M4LhNmlEPTB;MUCg{txO	NXuw[lkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H460	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLKZWdbOTBizszN	MW[3NkBp	NUni[XN[TE2VTx?=	NGjYZXFKSzVyPUGwJO69VQ>?	MofMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Calu-6	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\NNVAh\|ryP	NGXNXGo4OiCq	M1vvW2ROW09?	NYLYdmlNUUN3ME2xNEDPxE1?	M{TmVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HCC-2998	M4LWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPqcIFNOTBizszN	MXq3NkBp	NE\5OmhFVVOR	NHPMSWtKSzVyPUGwJO69VQ>?	M3T0c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
LS1034	NVq3XJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXBNnFFOTBizszN	M{\EPVczKGh?	M{jt[GROW09?	MYXJR\|UxRTFyIN88US=>	NHS2NZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CHP-212	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzyR4QyOCEQvF2=	NF;6fnE4OiCq	Ml[wSG1UVw>?	MYfJR\|UxRTFyIN88US=>	M13IZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-AS	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2xNEDPxE1?	Moq2O\|IhcA>?	NGTIV\|RFVVOR	MV7JR\|UxRTFyIN88US=>	MnfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
BFTC-905	M3HubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XlV\|ExKM7:TR?=	NFTuWo04OiCq	NV3VPHI{TE2VTx?=	NWeyPHNOUUN3ME2xNEDPxE1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HuT78	M4Xubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHwOogxOTBizszN	MV63NkBp	M4nQWWROW09?	MlHXTWM2OD13MjDuUS=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
RPMI-8226	NW\KdppQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TlUlExKM7:TR?=	M2XaW\|czKGh?	NWDucpd1TE2VTx?=	M372[WlEPTB;Mk[zJI5O	M{Pqb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
BC-3	NHvnWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G0WlExKM7:TR?=	NWf4eIFpPzJiaB?=	MojTSG1UVw>?	M3fQbmlEPTB;Mke3JI5O	M1;rbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
ACHN	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXW5eY1DOTBizszN	MWC3NkBp	M1XnNGROW09?	NULBeW9zUUN3ME2yPVQhdk1?	M4DvTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
JRT3-T35	M3L6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7v[HcyOCEQvF2=	NXf0PIRLPzJiaB?=	NFjadnBFVVOR	NUjXUnB2UUN3ME2yPVUhdk1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-MES-1	M4fvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3hTnQyOCEQvF2=	NXjob4FJPzJiaB?=	M1nG[GROW09?	M1TtZWlEPTB;M{K5JI5O	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CESS	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDuNVAh\|ryP	NICxOWw4OiCq	NXnITI4{TE2VTx?=	MoCzTWM2OD12OUegcm0>	MlzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
H4	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fpcVExKM7:TR?=	M4TsOVczKGh?	MWLEUXNQ	M2nubWlEPTB;NkG5JI5O	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
BC-1	M1fuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnX6NVAh\|ryP	NUCzelB5PzJiaB?=	MWXEUXNQ	MVLJR\|UxRTdyNDDuUS=>	M1js[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DB	MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnTOpMyOCEQvF2=	M2LZfFczKGh?	NY\HUmoxTE2VTx?=	NHXjfldKSzVyPUi3N{BvVQ>?	NH;qRWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
RPMI-6666	NIHufIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PjUFExKM7:TR?=	NEO5Rmw4OiCq	NHnFNVdFVVOR	M1vWbmlEPTB;OUK4JI5O	M{DPN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MC/CAR	M374UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr6fJdpOTBizszN	M3W4fVczKGh?	NHPRfoJFVVOR	Mor2TWM2OD1zLkCwNkDPxE1?	MnPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-1	M2DUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLVZpAyOCEQvF2=	MoTPO\|IhcA>?	M{PYe2ROW09?	MXLJR\|UxRTFwNUCxJO69VQ>?	NU\Z[ndyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CEM/C1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmq5NVAh\|ryP	M1LkO\|czKGh?	NWDtbXRETE2VTx?=	MkHUTWM2OD1zLke3N{DPxE1?	NYrxXG9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
GDM-1	M2G0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnN[WllOTBizszN	MnfnO\|IhcA>?	NHvzeVVFVVOR	NIXGNmNKSzVyPUGuPVk4KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HT-1080	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\ONVAh\|ryP	M1;KU\|czKGh?	MWjEUXNQ	MVjJR\|UxRTJwMEC0JO69VQ>?	MofoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HL-60	MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvDblZvOTBizszN	NYWwSlhFPzJiaB?=	MYTEUXNQ	MmnFTWM2OD1{LkG3PEDPxE1?	NInLN2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
C3A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nJUlExKM7:TR?=	NYnycWFRPzJiaB?=	NIHkTYlFVVOR	MW\JR\|UxRTVwNEG0JO69VQ>?	MnG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MES-SA	NFiyUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUC0OZh1OTBizszN	NIDFOY84OiCq	NW\rcHVbTE2VTx?=	M{\wXmlEPTB;Nj65PFkh\|ryP	NWeybXk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
22Rv1	NUjVeWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljQNVAh\|ryP	MVi3NkBp	M4jmfmROW09?	MonZTWM2OD1zMDFOwG0>	MmnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
647-V	NV[wOHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXmcHVrOTBizszN	Mn\iO\|IhcA>?	MYrEUXNQ	MWHJR\|UxRTFyIN88US=>	M1i1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
786-O	NV;JOFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vuNFExKM7:TR?=	Mn7UO\|IhcA>?	NGPFdZFFVVOR	NYD1[nI3UUN3ME2xNEDPxE1?	M1vNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A172	NVWyWJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zPe\|ExKM7:TR?=	NUnGXplIPzJiaB?=	NGXMWGdFVVOR	NYSyN49EUUN3ME2xNEDPxE1?	NEnPN2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A204	NYT4[IwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOwdnMyOCEQvF2=	M{W4VVczKGh?	M3:wSGROW09?	MXfJR\|UxRTFyIN88US=>	M1rHUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A427	M3PDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\WW\|ExKM7:TR?=	NHfoeGE4OiCq	MWfEUXNQ	MUjJR\|UxRTFyIN88US=>	NE\vem89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A431	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\NWXQyOCEQvF2=	M3GyVlczKGh?	NVP5T49xTE2VTx?=	MWHJR\|UxRTFyIN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A2780	M1[5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOxNEDPxE1?	M2\HU\|czKGh?	NYfuWpRITE2VTx?=	MYTJR\|UxRTFyIN88US=>	M3vxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
ARH-77	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rFVVExKM7:TR?=	NUXlWGNGPzJiaB?=	NUezdVhJTE2VTx?=	M2H0S2lEPTB;MUCg{txO	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Be(2)C	NWDlc49PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;GcVExKM7:TR?=	NX3PZplpPzJiaB?=	NFL2bYlFVVOR	NGru[4tKSzVyPUGwJO69VQ>?	NFHKdI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BT-20	NXT2c2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DpZVExKM7:TR?=	Mo[xO\|IhcA>?	MkTlSG1UVw>?	NXS4WFVkUUN3ME2xNEDPxE1?	M1voUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
BxPc3	M3qxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLaeI9vOTBizszN	M2L0OFczKGh?	M1rvRWROW09?	NGX1W\|VKSzVyPUGwJO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
C-4 I	NHy4eIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjodI0yOCEQvF2=	MoTzO\|IhcA>?	NGHJ[3NFVVOR	NVT3dnp5UUN3ME2xNEDPxE1?	NIXK[3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
C33A	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHrRWQyOCEQvF2=	NV7RR45VPzJiaB?=	MknySG1UVw>?	MYjJR\|UxRTFyIN88US=>	NFXvUXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CAL-27	NUDUWplMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvEWmZSOTBizszN	NGnGO404OiCq	MVHEUXNQ	MVLJR\|UxRTFyIN88US=>	MlL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CAL-62	Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzGW4luOTBizszN	M1jKXVczKGh?	M3\PXGROW09?	M3P0bmlEPTB;MUCg{txO	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Calu-3	Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzGNVAh\|ryP	MluzO\|IhcA>?	NFXWOoZFVVOR	NX7ad4o1UUN3ME2xNEDPxE1?	NGrCdGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CaOV3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:xXlExKM7:TR?=	MkDiO\|IhcA>?	NH22bm1FVVOR	NX6wUYQ3UUN3ME2xNEDPxE1?	M3q1VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CGTHW1	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnEXWxJOTBizszN	M1fCbFczKGh?	NXLIT4txTE2VTx?=	NFGxWoZKSzVyPUGwJO69VQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CHL-1	NYXuNGJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXexNEDPxE1?	NYO3dnBiPzJiaB?=	Mm\LSG1UVw>?	M4L5bWlEPTB;MUCg{txO	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Colo320DM	NEfvTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIq3W2gyOCEQvF2=	Mnu0O\|IhcA>?	M37afGROW09?	MXfJR\|UxRTFyIN88US=>	NYq4boF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Colo704	M17VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFO2WHIyOCEQvF2=	MWm3NkBp	NWHY[mdxTE2VTx?=	NYSxSIVrUUN3ME2xNEDPxE1?	NIfrSlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
COR-L23	NFPBUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYmzZ5ZFOTBizszN	M1zjTFczKGh?	M1zMXWROW09?	NETyPWdKSzVyPUGwJO69VQ>?	NWTjcY9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CRO-AP2	NXHqSGtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnEbXgyOCEQvF2=	M3jPeFczKGh?	Mln2SG1UVw>?	NXHSNmFpUUN3ME2xNEDPxE1?	NF6wbVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Daudi	M4XnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:xNEDPxE1?	MUW3NkBp	MWXEUXNQ	NYnLZZJNUUN3ME2xNEDPxE1?	NHyzZ5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
DOTC 24510	NXTrXGF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUixNEDPxE1?	MkG4O\|IhcA>?	MWTEUXNQ	NHnWdppKSzVyPUGwJO69VQ>?	M3\YVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DU-145	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXlcFNvOTBizszN	NWD5fYpMPzJiaB?=	MX\EUXNQ	M{fr[mlEPTB;MUCg{txO	NWjRZVg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
EB-3	M3jKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjFUVhiOTBizszN	NGjwWVU4OiCq	MV7EUXNQ	MoPUTWM2OD1zMDFOwG0>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
EFM-19	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TiZ\|ExKM7:TR?=	MUW3NkBp	NIHiWmtFVVOR	M1z2UGlEPTB;MUCg{txO	MkHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
EKVX	MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3v2PVExKM7:TR?=	MmTHO\|IhcA>?	MoTjSG1UVw>?	MkGwTWM2OD1zMDFOwG0>	NEP5ZpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
FaDu	NUDLV4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDkcWgyOCEQvF2=	M2\S[FczKGh?	NWTNZ3UzTE2VTx?=	M{ny[mlEPTB;MUCg{txO	NHn0b5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
G401	M{njfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXKNVAh\|ryP	NUWye\|V3PzJiaB?=	MVHEUXNQ	NVO4T4dZUUN3ME2xNEDPxE1?	M2KyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HCC-70	M3fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV2xNEDPxE1?	M2jJW\|czKGh?	NVfpcWc2TE2VTx?=	MnHPTWM2OD1zMDFOwG0>	NIDoNpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HCC-1954	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	MXu3NkBp	NH\WSmJFVVOR	MYfJR\|UxRTFyIN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Hela	NYrWdYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;mcYJiOTBizszN	M2\vflczKGh?	MlXtSG1UVw>?	MkO1TWM2OD1zMDFOwG0>	NHLGOVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Hep3B	NVPL[mFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37MU\|ExKM7:TR?=	M3HJd\|czKGh?	MWPEUXNQ	M3LhXmlEPTB;MUCg{txO	NYLJSmdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HMCB	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{G1T\|ExKM7:TR?=	MlGyO\|IhcA>?	M4HnNGROW09?	MlTZTWM2OD1zMDFOwG0>	NUXsfGt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HN5	M4XFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTPfoo4OTBizszN	M3vSclczKGh?	MmHQSG1UVw>?	M3[xOGlEPTB;MUCg{txO	NUTYfpRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HOS	M1PReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY[xNEDPxE1?	MmjLO\|IhcA>?	MlS5SG1UVw>?	MkLuTWM2OD1zMDFOwG0>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HPAF-II	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnkPJZOOTBizszN	MUG3NkBp	M1XvdGROW09?	MXnJR\|UxRTFyIN88US=>	NHyzWog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Hs746.T	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rEXVExKM7:TR?=	NHm0R\|E4OiCq	NHH0UFFFVVOR	MVrJR\|UxRTFyIN88US=>	MnzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HT	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUCxNEDPxE1?	MofzO\|IhcA>?	MWXEUXNQ	MULJR\|UxRTFyIN88US=>	Mlr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HT-3	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorBNVAh\|ryP	NILYWXQ4OiCq	M4XPRmROW09?	M1rtW2lEPTB;MUCg{txO	MknzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HuNS-1	NEnvbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\nNVAh\|ryP	MVK3NkBp	Mny0SG1UVw>?	M2LHOWlEPTB;MUCg{txO	M3v0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
IGROV1	M4LM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnxd24yOCEQvF2=	NGL5T4U4OiCq	NYTUc\|dZTE2VTx?=	NUi3RZBrUUN3ME2xNEDPxE1?	NULRWm5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
J82	NIHmfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHoOlU3OTBizszN	M3;Q[\|czKGh?	NV3mWWxWTE2VTx?=	MkDYTWM2OD1zMDFOwG0>	M3H2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
JM1	NFjUcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTDNVAh\|ryP	NEPHTlI4OiCq	M1ixVmROW09?	M4TCNWlEPTB;MUCg{txO	NHXzeJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Kato III	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjMNVAh\|ryP	MUG3NkBp	MljUSG1UVw>?	NVLtOXVDUUN3ME2xNEDPxE1?	M324bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KHOS-240S	NX\rd5dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjtNmpCOTBizszN	NUHMcHZSPzJiaB?=	MnnwSG1UVw>?	NHXHWHhKSzVyPUGwJO69VQ>?	MnT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
KM-12	NXezfYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVexNEDPxE1?	M1LTeFczKGh?	MULEUXNQ	M{nMXmlEPTB;MUCg{txO	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
KPL-1	M{jJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[0NVAh\|ryP	MYO3NkBp	M{HKVWROW09?	M3fvPGlEPTB;MUCg{txO	NHTJbHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
KYSE-30	M1j3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHXOZgyOCEQvF2=	MnrLO\|IhcA>?	NHHKOFRFVVOR	M2DIT2lEPTB;MUCg{txO	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
LNCaP	NF71WFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jublExKM7:TR?=	M2PvV\|czKGh?	NYHY[mR[TE2VTx?=	NEfUO5hKSzVyPUGwJO69VQ>?	NUfQbJlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MCF-7	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnCWW01OTBizszN	MmPDO\|IhcA>?	MoS1SG1UVw>?	MWHJR\|UxRTFyIN88US=>	MmW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MC-IXC	NV;rcnNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYOxNEDPxE1?	NELkfnA4OiCq	NY\W[GRTTE2VTx?=	MlXhTWM2OD1zMDFOwG0>	NFL6cnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MDA-MB-175 VII	M4jLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7JfnEyOCEQvF2=	M4[x[FczKGh?	NEH6bXlFVVOR	M3XaZmlEPTB;MUCg{txO	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MDA-MB-468	NX3l[G5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWX1NolOOTBizszN	MVi3NkBp	MV7EUXNQ	Ml3iTWM2OD1zMDFOwG0>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MiaPaCa	NFXQVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTu[mVqOTBizszN	MkHCO\|IhcA>?	NEKxcIZFVVOR	MXjJR\|UxRTFyIN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Molt-4	NGjqToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\GVVExKM7:TR?=	MVy3NkBp	MnfBSG1UVw>?	M{\PRWlEPTB;MUCg{txO	NYXCU3NwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-ADR/RES	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHhNVAh\|ryP	MonMO\|IhcA>?	MXfEUXNQ	NG\lPIdKSzVyPUGwJO69VQ>?	NEDzcGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H69	NV25[Fh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;HNY9COTBizszN	MmjTO\|IhcA>?	NWTGS4xbTE2VTx?=	MljtTWM2OD1zMDFOwG0>	Ml:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H82	MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf5fFYyOCEQvF2=	NF3DU2Q4OiCq	MXrEUXNQ	NEe2emtKSzVyPUGwJO69VQ>?	NHjDT2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-N87	NY\0VZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTrSpcyOCEQvF2=	MXW3NkBp	MnjhSG1UVw>?	NInScnVKSzVyPUGwJO69VQ>?	NXHYb41NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H146	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXDPFEyOCEQvF2=	NFq0UFk4OiCq	M3TrOGROW09?	MofzTWM2OD1zMDFOwG0>	NXH5eXpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H157	M{fZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTKWJJKOTBizszN	NGO1[mo4OiCq	NHK2RYhFVVOR	NV3RTmxoUUN3ME2xNEDPxE1?	M3LFV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H187	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHCT5B[OTBizszN	M37qZlczKGh?	NIixVGhFVVOR	M2jMVmlEPTB;MUCg{txO	MnTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H209	NHLvc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4f4TlExKM7:TR?=	NYm3eXNkPzJiaB?=	NG\JT5VFVVOR	NUfleZB[UUN3ME2xNEDPxE1?	M2P1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H226	NHXjOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHINVAh\|ryP	MXW3NkBp	M3rkNWROW09?	Ml\VTWM2OD1zMDFOwG0>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H292	NHrVUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\WS48yOCEQvF2=	NVLPdWJnPzJiaB?=	NEP6V4ZFVVOR	M1Xs[2lEPTB;MUCg{txO	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H322	NWXrW4lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TBdVExKM7:TR?=	MmXiO\|IhcA>?	NEDRSohFVVOR	MmD2TWM2OD1zMDFOwG0>	NX;zdXNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H358	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjn[VRsOTBizszN	MWK3NkBp	NFjicIJFVVOR	M2jKPGlEPTB;MUCg{txO	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H520	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKxNEDPxE1?	NXXx[5ZPPzJiaB?=	MkHkSG1UVw>?	Mn21TWM2OD1zMDFOwG0>	NIDTeZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H526	NEfTSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO2c2YyOCEQvF2=	MmOyO\|IhcA>?	Ml6xSG1UVw>?	M3rTV2lEPTB;MUCg{txO	MljGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H630	M33mPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\EdGU2OTBizszN	NH;T[\|Y4OiCq	MWrEUXNQ	NIfPbZpKSzVyPUGwJO69VQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H661	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7oNVAh\|ryP	MVW3NkBp	MWnEUXNQ	M33YcWlEPTB;MUCg{txO	NVPs[2VLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H716	Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;yVmRXOTBizszN	M{X1dFczKGh?	MVvEUXNQ	NYPHbZBIUUN3ME2xNEDPxE1?	MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H1563	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2T6VlExKM7:TR?=	NFS5OVA4OiCq	NFjWWnhFVVOR	NFjo[INKSzVyPUGwJO69VQ>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H1792	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW[xNEDPxE1?	MW[3NkBp	M13nU2ROW09?	NGjXcolKSzVyPUGwJO69VQ>?	NXP1VJZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H2030	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXK[Fc2OTBizszN	MV23NkBp	NXfOfIQxTE2VTx?=	NI\1e\|RKSzVyPUGwJO69VQ>?	MoDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H2052	NIDtS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3SyN\|ExKM7:TR?=	NES4OoY4OiCq	MmrCSG1UVw>?	NYi2R4RUUUN3ME2xNEDPxE1?	M1ixZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H2122	M4r4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fmZVExKM7:TR?=	MWC3NkBp	MnqySG1UVw>?	MoLwTWM2OD1zMDFOwG0>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H2228	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PYSlExKM7:TR?=	NIntbY04OiCq	M4DUcmROW09?	NWPX[GZxUUN3ME2xNEDPxE1?	NH\1dpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
OE-19	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fFWVExKM7:TR?=	NXWw[nNwPzJiaB?=	MW\EUXNQ	MnXxTWM2OD1zMDFOwG0>	NX3VXlk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OE-21	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml20NVAh\|ryP	NWnXUZNvPzJiaB?=	MXnEUXNQ	MVTJR\|UxRTFyIN88US=>	NIG3Ono9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
OE-33	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXMNVAh\|ryP	NWLO[nh5PzJiaB?=	MX7EUXNQ	M2L5bmlEPTB;MUCg{txO	M{j3TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHyWZl2OTBizszN	NX\wWY1HPzJiaB?=	MkLPSG1UVw>?	M3XKfWlEPTB;MUCg{txO	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
OVCAR-4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7UNVAh\|ryP	MlPDO\|IhcA>?	NEXofpZFVVOR	MULJR\|UxRTFyIN88US=>	NH7rbWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
OVCAR-5	M1PNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DoTVExKM7:TR?=	MYG3NkBp	M1;PV2ROW09?	M13vRWlEPTB;MUCg{txO	M4rqUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
P3HR-1	NXPrbmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	NEDHT3U4OiCq	MkXPSG1UVw>?	MmrITWM2OD1zMDFOwG0>	M1\D[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
PC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYOxZZZUOTBizszN	MX[3NkBp	MWnEUXNQ	NGHaT\|lKSzVyPUGwJO69VQ>?	M2nGWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Raji	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXyxNEDPxE1?	MlnCO\|IhcA>?	M{nPemROW09?	Mn\qTWM2OD1zMDFOwG0>	MnToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RD	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPZbGIyOCEQvF2=	NX[0WpByPzJiaB?=	MmDGSG1UVw>?	NILPT\|VKSzVyPUGwJO69VQ>?	MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RD-ES	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PCUlExKM7:TR?=	NFTITWU4OiCq	NHvieWxFVVOR	NHzmXW1KSzVyPUGwJO69VQ>?	NWe2[WpKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
RL	Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTPW4FbOTBizszN	MkPBO\|IhcA>?	NFL5VWRFVVOR	NYn1dm1JUUN3ME2xNEDPxE1?	M3HpRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SaOS2	M1fve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS5NVAh\|ryP	NGPRbm44OiCq	MnTNSG1UVw>?	MnfETWM2OD1zMDFOwG0>	NHzTZYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SCC-9	NGPiNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUW5OoxlOTBizszN	MoHBO\|IhcA>?	MVrEUXNQ	M4TCfmlEPTB;MUCg{txO	NETPVoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SCC-12	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHabXMyOCEQvF2=	MlPjO\|IhcA>?	MmjrSG1UVw>?	M1SxfmlEPTB;MUCg{txO	NF\QfYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SCC-13	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUmxNEDPxE1?	MmrEO\|IhcA>?	MUnEUXNQ	M1nqTWlEPTB;MUCg{txO	M3uzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-15	NXHmOHlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDafVZ3OTBizszN	MoPJO\|IhcA>?	Mnj5SG1UVw>?	MnTDTWM2OD1zMDFOwG0>	NXjrPXI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SCC-25	NWDr[5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\qUWcyOCEQvF2=	NWrwN28{PzJiaB?=	NF7ObmdFVVOR	MUfJR\|UxRTFyIN88US=>	NX3FdW1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SCLC-3	NWXoRWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInBOY4yOCEQvF2=	MYS3NkBp	MVLEUXNQ	M2XHOmlEPTB;MUCg{txO	Mmq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SF-268	NYrkVWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSxNEDPxE1?	M33pUlczKGh?	NV7JeJlRTE2VTx?=	Mo\iTWM2OD1zMDFOwG0>	M{nsbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SF-295	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYSxNEDPxE1?	NWPae3pJPzJiaB?=	M4PZOWROW09?	NUC1V3FEUUN3ME2xNEDPxE1?	M3fsOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SJRH30	MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPCOlUyOCEQvF2=	M37rRVczKGh?	NYfzUJBtTE2VTx?=	MYfJR\|UxRTFyIN88US=>	NV7wcZQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-BR-3	NGDLcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxNEDPxE1?	MoSyO\|IhcA>?	NEn2Zo1FVVOR	NYnWOmpJUUN3ME2xNEDPxE1?	M4fD[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-LMS-1	NWC3WWI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ToNFExKM7:TR?=	NEnrdHc4OiCq	MVzEUXNQ	MVLJR\|UxRTFyIN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-N-DZ	NFHUVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfiPGwyOCEQvF2=	M1jVXlczKGh?	MVHEUXNQ	MXHJR\|UxRTFyIN88US=>	M1rLZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-F1	M3[1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPPToplOTBizszN	MXi3NkBp	M3v5SWROW09?	NUfKfpY1UUN3ME2xNEDPxE1?	NHTKdow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SKOV-3	NIDx[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm1Spo4OTBizszN	M2rVOFczKGh?	NIHWR4lFVVOR	MoGzTWM2OD1zMDFOwG0>	NHjndJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-UT-1	NXHNTWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfFNVAh\|ryP	NUD0cXZJPzJiaB?=	MXzEUXNQ	Mo\5TWM2OD1zMDFOwG0>	NW\NeY9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SN12C	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPWNVAh\|ryP	MVS3NkBp	M3LycGROW09?	MWnJR\|UxRTFyIN88US=>	MlnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNB-19	NVzrU\|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fHTFExKM7:TR?=	MlLHO\|IhcA>?	MmTaSG1UVw>?	M3[3e2lEPTB;MUCg{txO	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SNU-5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[xNEDPxE1?	NFXnTHg4OiCq	M{OyOWROW09?	NYPSV21IUUN3ME2xNEDPxE1?	NGf0coc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-16	M{fxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjhV3QyOCEQvF2=	MlnSO\|IhcA>?	NYnudZB4TE2VTx?=	M1jQbmlEPTB;MUCg{txO	NEXDV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-398	M4PrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHMeXgyOCEQvF2=	NWfzPWtIPzJiaB?=	MV;EUXNQ	MUXJR\|UxRTFyIN88US=>	MnexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-449	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6xNEDPxE1?	M2jVeVczKGh?	M1myXGROW09?	NGKwZ2hKSzVyPUGwJO69VQ>?	MoG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SR	NU\kZm1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEf4T4oyOCEQvF2=	M3LDNlczKGh?	NEO0cWhFVVOR	M4T6bmlEPTB;MUCg{txO	M2nJRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
ST486	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvVWHVtOTBizszN	NIqxWVE4OiCq	NWT2SJZTTE2VTx?=	NWHZRlRvUUN3ME2xNEDPxE1?	NYi2[HNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW579	M{nRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXGxNEDPxE1?	NXS1R4FFPzJiaB?=	MXTEUXNQ	M2jnV2lEPTB;MUCg{txO	M1[4[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW684	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLqVowyOCEQvF2=	NYHrU4pMPzJiaB?=	MnjYSG1UVw>?	Mn;vTWM2OD1zMDFOwG0>	M{jIcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW-780	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTuNVAh\|ryP	NELDWJc4OiCq	M{HoPWROW09?	NFryVIlKSzVyPUGwJO69VQ>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW900	NID3VVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPW[\|UyOCEQvF2=	MY[3NkBp	NFrw[3lFVVOR	NF;qOJJKSzVyPUGwJO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW1088	NHTkW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2C3fFExKM7:TR?=	NVi0XHpHPzJiaB?=	MVHEUXNQ	MWrJR\|UxRTFyIN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW1463	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PyZVExKM7:TR?=	NXPUW5lDPzJiaB?=	Mn;NSG1UVw>?	M2jYUGlEPTB;MUCg{txO	MmfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW1990	M2L6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUG3N45FOTBizszN	MYO3NkBp	MXXEUXNQ	M1PRcmlEPTB;MUCg{txO	NX\kVoJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
T47D	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYm5TYJYOTBizszN	NHi2PGg4OiCq	M2\rd2ROW09?	M1HySGlEPTB;MUCg{txO	NW\kTpdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
TE381.T	NVfTcJhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\t[WN1OTBizszN	NGXMZWw4OiCq	MUnEUXNQ	NULlfWd6UUN3ME2xNEDPxE1?	NI[0eXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
TK-10	NWK1PW53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jYTlExKM7:TR?=	MWm3NkBp	Mlv4SG1UVw>?	NWnHS5ZZUUN3ME2xNEDPxE1?	M{H3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
U2OS	NETQRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rDfVExKM7:TR?=	NH:zXYY4OiCq	M1f6S2ROW09?	NXvofHNxUUN3ME2xNEDPxE1?	Mn[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
U251	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HIWVExKM7:TR?=	MU[3NkBp	MlvnSG1UVw>?	MkDvTWM2OD1zMDFOwG0>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
UACC-812	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXuxNEDPxE1?	MkjZO\|IhcA>?	M2fTOWROW09?	M4LLSGlEPTB;MUCg{txO	M3:zfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
YAPC	M4f5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjKfo0yOCEQvF2=	NH7rNFI4OiCq	NU\XdHR5TE2VTx?=	M4PwZmlEPTB;MUCg{txO	NEPZUI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ZR-75-1	NIfTc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXSxNEDPxE1?	NE\XV5k4OiCq	NXHDR3Z4TE2VTx?=	MYnJR\|UxRTFyIN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A375	M12zcWZ2dmO2aX;uJIF{e2G7	MVGxMlIh\|ryP	NVXPXlc5PCCq	MWDEUXNQ	NGDRbpBKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN6OUS3NUc,OjJ\|OEm0O\|E9N2F-
YUSIT1	M1K2NWZ2dmO2aX;uJIF{e2G7			NES1VIVFVVOR	NVrucIpvemWmdXPl[EB{\W6\|aYTpeol1gSC5aYToJGlEPTBiPjCwMlUh\|ryP	M4jU[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i5OFcyLz5{MkO4PVQ4OTxxYU6=
MeWo	NYTvbVBlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MWHEUXNQ	NIjFXIhKSzVyIE2gPVg4KG6P	M4rPXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEG4OVI1Lz5{NkCxPFUzPDxxYU6=
WiDr	M{G4XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHv3bYlFVVOR	NIn3SVlKSzVyIE2gO\|Yhdk1?	NVO3UZlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVg2OjRpPkK2NFE5PTJ2PD;hQi=>
Colo-205	NViwSJZ7TnWwY4Tpc44h[XO\|YYm=	Mlv1NUDPxE1?	NUPJR5BXPCCm	MkfTSG1UVw>?	MWLJcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU>	NX63dYVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFEyPTJpPkK1N\|gyOTV{PD;hQi=>
RBW-1	M3vnTWZ2dmO2aX;uJIF{e2G7	NEHGTIMyKM7:TR?=		M4rJO2ROW09?	Mln3Uo8hemWmdXP0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	M1;jO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi1OlkxLz5{NEi4OVY6ODxxYU6=
RBO-1	MmjGSpVv[3Srb36gZZN{[Xl?	Mmr5NUDPxE1?		MkHRSG1UVw>?	NGnhdZJKdmirYnn0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
RBO-2	NGG5epVHfW6ldHnvckBie3OjeR?=	NFztZ\|MyKM7:TR?=		MXTEUXNQ	NXW0NoJsUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?	M3qwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi1OlkxLz5{NEi4OVY6ODxxYU6=
RBOW	NYjkZnFGTnWwY4Tpc44h[XO\|YYm=	MYqxJO69VQ>?		M4\QNmROW09?	MWHJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEW2PVAoRjJ2OEi1OlkxRC:jPh?=
M257	M3jlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnqcJUyODBibl2=	NWfoe2EyPzJiaB?=		NHjpelhFd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NHTjSFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
LCP	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofJNVAxKG6P	MXW3NkBp		MWjJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u	M2PyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G3OFQ3Lz5{M{OxO\|Q1PjxxYU6=
WM266	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHOSG1zOTByIH7N	MoTEO\|IhcA>?		NXfHNW1PUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFFFKG23dHHueIF1cW:w	M33YRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G3OFQ3Lz5{M{OxO\|Q1PjxxYU6=
M257	NIr6cGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mke3NVAxKG6P	M4HwZlczKGh?		MVvEc4V{KG6xdDDpcohq[mm2IFXST\|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ?	NHHadm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
LCP	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LEUlExOCCwTR?=	NIXPZm04OiCq		MorLTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzN{S0Okc,OjN\|MUe0OFY9N2F-
WM266	NWW1dng3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIi2[5EyODBibl2=	MVK3NkBp		MmrvTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w	M{e1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G3OFQ3Lz5{M{OxO\|Q1PjxxYU6=
A375	NXr4bGVpSlKDRjDjc41x\XSrdHn2[UBjcW6maX7nJIF{e2G7		MVOxOUBucW5?		NETNSG1KSzVyIE2gNE4xODZizszN	NYjV[FV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	NGDFeFFHfW6ldHnvckBie3OjeR?=		MXG3NkBp		NULZO5dmUUN3MDC9JFAvODFzIN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4NUiwOEc,OjV7NkW4NFQ9N2F-
A375	MVfBVmFHKGOxbYDleIl1cX[nIHLpcoRqdmdiYYPzZZk>		NX6zT21wOTVibXnu		NXTvdpc6UUN3MDC9JFAvODJ4IN88US=>	NGLPO\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2OVgxPCd-MkW5OlU5ODR:L3G+
A375	MVXDVmFHKGOxbYDleIl1cX[nIHLpcoRqdmdiYYPzZZk>		NHLVRnIyPSCvaX6=		NY\a[nNpUUN3MDC9JFAvOTVizszN	M1\LdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[1PFA1Lz5{NUm2OVgxPDxxYU6=
HCT116	MnztSpVv[3Srb36gZZN{[Xl?				NVvVfmpEUUN3MDC9JFUvQDhizszN	NFjIfGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2OVgxPCd-MkW5OlU5ODR:L3G+
A375	M4[5fmZ2dmO2aX;uJIF{e2G7		NVP1THNvOSCq		M3ftc2lEPTBiPTCwMlAxOSEQvF2=	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOEW2O\|IoRjJ5MEi1OlczRC:jPh?=
MIAPaCa2	MXXGeY5kfGmxbjDhd5NigQ>?		MVGxJIg>		NGXkZ4hGSzVyIE2gNE42OjlizszN	NFSwVZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4OVY4Oid-MkewPFU3PzJ:L3G+
A375	MXLGeY5kfGmxbjDhd5NigQ>?				M3m5SmlEPTBiPTCwMlAxPCEQvF2=	M2HLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[xPFI4Lz5{OUS2NVgzPzxxYU6=
SK-MEL-28	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=		NGCyNYc4OiCq		M2PuXWlEPTBiPTCwMlA1OyEQvF2=	MnXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NkG4NlcoRjJ7NE[xPFI4RC:jPh?=
Sf9	NV36U5lUTnWwY4Tpc44h[XO\|YYm=		MVq2NEBucW5?		NIXLXJlKSzVyIE2gNE4xODlizszN	NHTZbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFE{Pyd-Mke3O\|QyOzd:L3G+
SK-MEL-28	NInNUFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M330XlQ5KGh?		Moj1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suVUWOLUK4JINmdGy\|IHjhdoJwemmwZzDCVmFHKFZ4MEDFJI12fGGwdDDt[YF{fXKnZDDh[pRmeiB2ODDodpMhemW\|YYr1dolvKGG\|c3H5	MlXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxN\|coRjJ5N{e0NVM4RC:jPh?=
SK-MEL-28	NIjyRWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml[yOFghcA>?		NVToVYhQT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI5KGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBxemWrbnP1ZoF1\WRiZn;yJFEhcHJiZn;scI94\WRiYomgbZJz[WSrYYTpc44hd2ZiMT6xN{BsXy:vMjDVWk1tcWeqdDDmc5IhPSCvaX7zJI1m[XO3cnXkJIFnfGW{IES4JIhzeyC{ZYPhfpVzcW5iYYPzZZk>	NW\Ib3RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
SK-MEL-28	MnjGR5l1d3SxeHnjbZR6KGG\|c3H5		NV\Y[GhIPDhiaB?=		MVPDfZRwe3SjdHnjJIFkfGm4aYT5JIlvKGi3bXHuJHNMNU2HTD2yPEBk\WyuczDoZZJjd3KrbnegRnJCTiCYNkCwSUBufXSjboSgZZQhOSCjbnSgN\|AhfU1ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJJJme2G8dYLpckBie3OjeR?=	NGXXWFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFE{Pyd-Mke3O\|QyOzd:L3G+
DAOY	NVzURpYxWHKrbXHyfUB{[3KnZX6gZZN{[Xl?				NVrBfYY4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NVTEbpk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MX;Qdolu[XK7IIPjdoVmdiCjc4PhfS=>				NWHM[HlHeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NV7KSmpoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NY\jNlFVWHKrbXHyfUB{[3KnZX6gZZN{[Xl?				NF7KeG9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	Mlr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	GSK2118436A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04547946	Not yet recruiting	Drug: dabrafenib + trametinib	Malignant Melanoma	Novartis Pharmaceuticals\|Novartis	April 30 2021	--
NCT04775095	Recruiting	--	Non Small Cell Lung Cancer\|BRAF V600 Mutation	Intergroupe Francophone de Cancerologie Thoracique\|Novartis	March 8 2021	--
NCT04666272	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	December 31 2020	--
NCT04452877	Active not recruiting	Drug: Dabrafenib\|Drug: Trametinib	Carcinoma Non-Small-Cell Lung	Novartis Pharmaceuticals\|Novartis	August 19 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. LY03009120 induces autophagy. Phase 1.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204, RO5185426) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib (BAY 43-9006)

Sorafenib (BAY 43-9006, NSC-724772) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib (BAY 43-9006) tosylate

Sorafenib (BAY 43-9006) tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. GW5074 inhibits LK-induced apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)